Track topics on Twitter Track topics that are important to you
We strive to improve people’s lives by applying our technology and other resources to the discovery and development of new products and processes that benefit the health, well-being and financial economy of patients, consumers and partner companies around the world.
The Company’s primary corporate goal is to build a profitable and sustainable business around its core competencies in compound and pathway discovery and development, and from the commercialisation (by Evolva or its partners) of its product candidates.
We aim to “embed” the results of our technology in products or processes that are partnered with companies and organisations with the expertise and resources to commercialise the products.
Our platform is applicable to a range of industries, including the pharmaceutical, food, chemical and energy sectors. Our main focus is on high value products in the healthcare, nutrition and personal care space.
To achieve this goal the Company intends to employ the following key strategies:
By building a balanced product portfolio, the Company aims to defray risk by increasing the probability of clinical and commercial success and reducing its exposure to the impact of any one product failure. In order to implement this strategy, the Company carries out its own product development programmes, but also plans to partner with third parties in order to defray the cost and risk of clinical development (particularly the cost of late stage clinical trials) and expand marketing power. Although such partnerships may enable the Company to commercialise any approved products without developing its own sales force, the Company may also decide to market approved products on its own in selected indications compatible with its overall resources (e.g., orphan indications, products sold to specialists).
We intend to focus on differentiated product candidates that target significant unmet medical needs because they have the potential to provide greater options and choices for the patient or consumer and better pricing potential for the supplier. The Company has chosen to emphasise cardio-renal and infectious disease indications because:
The Company emphasises small molecule compounds that can be delivered orally. Oral administration is often the most convenient administration route for patients and the most cost-effective for society. In most cases small molecules are also cheaper to manufacture than biologics.
Our proprietary discovery technology platform uses a “disruptive” technological approach to the creation of novel small compounds that differs sharply from the prevailing approaches in the pharmaceutical industry today (i.e., synthetic chemistry and/or protein engineering). As a result, we expect to create compounds with different properties from those discovered by the majority of pharmaceutical companies. We plan to leverage our discovery technology not only to expand its own pipeline, but also to attract third party partners interested in using our technology in their own areas of interest.
The Company already generates revenues from discovery partnerships with various third parties and plans to maintain and expand its partnerships in both discovery (based primarily on our technology platform) and development (based primarily on our compounds) in the future. The Company sees these partnerships as an important element of its strategy for three main reasons:
In addition to partnerships in the pharmaceutical sector, we see opportunities to partner in sectors such as bio-defence, pharmaceutical intermediates, industrial chemicals and similar sectors.
Phone: 41 61 485 2000
Fax: 41 61 485 2001
MEDIENMITTEILUNG Evolva Aktionäre stimmen dem Antrag an der AGV zu DIESE UNTERLAGEN SIND NICHT ZUR (DIREKTEN ODER INDIREKTEN) VERÖFFENTLICHUNG, VERTEILUNG ODER WEITERGABE IN DEN USA, IN KANADA, JA.....
Dies teilt die an der SIX kotierte Evolva am Donnerstag mit. Die Transaktion führt den Angaben zufolge zu einem Bruttoerlös von rund 21,1 Mio CHF. Nach Abwicklung der Privatplatzierungen würden Pic...
(Meldung um letzten Absatz mit Aktienkurs ergänzt) Reinach (awp) - Evolva hat im Vorfeld der am Berichtstag stattfindenden ausserordentlichen Generalversammlung (aoGV) die finalen Bedingungen für d....
Reinach - Evolva hat nach vorläufigen Zahlen im vergangenen Geschäftsjahr seine Produktumsätze auf 2,0 Mio CHF nach 1,1 Mio im Vorjahr gesteigert. Das Wachstum führt das Unternehmen in einer Medie...
MEDIENMITTEILUNG Evolva kündigt den Preis für die Privatplatzierung an Pictet Asset Management und Cologny Advisors LLP an DIESE UNTERLAGEN SIND NICHT ZUR (DIREKTEN ODER INDIREKTEN) VERÖFFENTLICHU....
MEDIENMITTEILUNG Evolva gibt die vorläufigen Finanzkennzahlen für 2017 bekannt und informiert über die aktuelle Geschäftsentwicklung 25. Januar 2018 - Evolva (SIX: EVE) gibt die vorläufigen, unge...
Reinach (awp) - Evolva hat nach vorläufigen Zahlen im vergangenen Geschäftsjahr seine Produktumsätze auf 2,0 Mio CHF nach 1,1 Mio im Vorjahr gesteigert. Das Wachstum führt das Unternehmen in einer...
(Aktualisiert nach aoGV) Reinach (awp) - Die Evolva-Aktionären haben der geplanten ordentlichen Kapitalerhöhung durch eine Bezugsrechtsemission mit Abschlag zum Börsenkurs mit grosser Mehrheit zuge...
Evolvaâs mission is to discover and provide innovative, sustainable ingredients for health, nutrition and wellness. Evolva uses biosynthetic and evolutionary technologies to ...
We strive to improve people’s lives by applying our technology and other resources to the discovery and development of new products and processes that benefit the health, well-being and financ...
We strive to improve people’s lives by applying our technology and other resources to the discovery and development of new products and processes that benefit the health, well-being and financial ec...
We have published hundreds of Evolva SA news stories on BioPortfolio along with dozens of Evolva SA Clinical Trials and PubMed Articles about Evolva SA for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Evolva SA Companies in our database. You can also find out about relevant Evolva SA Drugs and Medications on this site too.
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...